| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00281-008-0111-X |
| P698 | PubMed publication ID | 18340447 |
| P2093 | author name string | Anthony P Adamis | |
| Adrienne J Berman | |||
| P2860 | cites work | Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1 | Q24323317 |
| Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin | Q28185699 | ||
| Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression | Q28192264 | ||
| Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects | Q28193542 | ||
| Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy | Q28218437 | ||
| A novel inflammatory pathway involved in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5 | Q28249427 | ||
| Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation | Q28285595 | ||
| Tumor necrosis factor-alpha in diabetic plasma increases the activity of core 2 GlcNAc-T and adherence of human leukocytes to retinal endothelial cells: significance of core 2 GlcNAc-T in diabetic retinopathy | Q28289690 | ||
| Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition | Q28343572 | ||
| Leukocyte-mediated endothelial cell injury and death in the diabetic retina | Q28345653 | ||
| The renin-angiotensin and the kallikrein-kinin systems | Q28609697 | ||
| Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. | Q30356505 | ||
| Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. | Q30834539 | ||
| Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization | Q30969814 | ||
| Macrophage depletion inhibits experimental choroidal neovascularization | Q31150851 | ||
| Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. | Q32041632 | ||
| Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy | Q33270090 | ||
| Kinin receptors in pain and inflammation | Q34100735 | ||
| Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. | Q34280300 | ||
| Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. | Q34292373 | ||
| Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders | Q34292807 | ||
| Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy | Q34324536 | ||
| Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy | Q34402812 | ||
| Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate | Q34409210 | ||
| Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration | Q34425420 | ||
| Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. | Q34432617 | ||
| A choice of death--the signal-transduction of immune-mediated beta-cell apoptosis | Q34495385 | ||
| Vascular endothelial growth factor: basic science and clinical progress | Q34549887 | ||
| Standards of medical care in diabetes--2007. | Q34595288 | ||
| Molecular understanding of hyperglycemia's adverse effects for diabetic complications | Q35005662 | ||
| Diabetic retinopathy: more than meets the eye. | Q35036623 | ||
| Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy | Q35102944 | ||
| The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction | Q35148421 | ||
| Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha | Q35209149 | ||
| Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy | Q35589524 | ||
| Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo | Q35747338 | ||
| Relationship of polymorphonuclear leukocytes to capillary dropout in the human diabetic choroid. | Q35763445 | ||
| A central role for inflammation in the pathogenesis of diabetic retinopathy | Q44961996 | ||
| Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. | Q45052632 | ||
| Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone | Q45185695 | ||
| Expression of acute-phase response proteins in retinal Müller cells in diabetes | Q45205307 | ||
| Sequential induction of angiogenic growth factors by TNF-alpha in choroidal endothelial cells | Q46112304 | ||
| Regression of neovascular age-related macular degeneration following infliximab therapy | Q46378170 | ||
| Neutrophils are associated with capillary closure in spontaneously diabetic monkey retinas | Q46458775 | ||
| Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy | Q46458778 | ||
| Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema | Q46475996 | ||
| Effects of a selective bradykinin B1 receptor antagonist on increased plasma extravasation in streptozotocin-induced diabetic rats: distinct vasculopathic profile of major key organs | Q46476328 | ||
| Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy | Q46493637 | ||
| A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. | Q46595124 | ||
| Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy | Q46667958 | ||
| A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema | Q46695946 | ||
| Serum inflammatory markers in diabetic retinopathy | Q46774828 | ||
| Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals | Q46847276 | ||
| Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy | Q46900649 | ||
| CD4-CD8 and CD28 expression in T cells infiltrating the vitreous fluid in patients with proliferative diabetic retinopathy: a flow cytometric analysis. | Q47623063 | ||
| Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. | Q47681650 | ||
| Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. | Q48024877 | ||
| A prize catch for diabetic retinopathy | Q48331968 | ||
| Triamcinolone acetonide protects the rat retina from STZ-induced acute inflammation and early vascular leakage. | Q50464660 | ||
| Glial reactivity, an early feature of diabetic retinopathy. | Q50511477 | ||
| Expression of CD18 on the neutrophils of patients with diabetic retinopathy. | Q53610983 | ||
| A morphologic and autoradiographic study of cell death and regeneration in the retinal microvasculature of normal and diabetic rats. | Q54703129 | ||
| Valsartan but not Atenolol Improves Vascular Pathology in Diabetic Ren-2 Rat Retina | Q60169547 | ||
| Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema | Q60197414 | ||
| Platelet expression of tumour necrosis factor-alpha (TNF-alpha), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy | Q63407539 | ||
| Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group | Q69489643 | ||
| Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group | Q70215909 | ||
| Platelet aggregation and coagulation in the pathogenesis of diabetic retinopathy in rats | Q70826577 | ||
| Cell surface morphology identifies microglia as a distinct class of mononuclear phagocyte | Q71511663 | ||
| Hypoxic regulation of vascular endothelial growth factor in retinal cells | Q71559437 | ||
| [TNF-alpha level in the vitreous body. Increase in neovascular eye diseases and proliferative diabetic retinopathy] | Q72173190 | ||
| An association in non-insulin-dependent diabetes mellitus subjects between susceptibility to retinopathy and tumor necrosis factor polymorphism | Q73350710 | ||
| Catalogue of soluble proteins in human vitreous humor by one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrospray ionization mass spectrometry including seven angiogenesis-regulating factors | Q73580396 | ||
| The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization | Q73587530 | ||
| Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes | Q73640405 | ||
| Intracellular pool of vascular endothelial growth factor in human neutrophils | Q73838822 | ||
| Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats | Q74052511 | ||
| Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus | Q74058742 | ||
| Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy | Q74424369 | ||
| Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy | Q74760311 | ||
| DIABETIC RETINOPATHY AND RHEUMATOID ARTHRITIS | Q76819514 | ||
| Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures | Q78570627 | ||
| A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema | Q79165166 | ||
| Vascular endothelial growth factor is a critical stimulus for diabetic macular edema | Q79259315 | ||
| Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology | Q79678216 | ||
| Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy | Q79781098 | ||
| Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy | Q79826274 | ||
| Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy | Q80020556 | ||
| Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema | Q80175166 | ||
| Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy | Q80538280 | ||
| The effect of long-term treatment with sulindac on the progression of diabetic retinopathy | Q80590780 | ||
| Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway | Q80853991 | ||
| Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab | Q81334004 | ||
| Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy | Q81473347 | ||
| Effector function of diabetogenic CD4 Th1 T cell clones: a central role for TNF-alpha | Q81512331 | ||
| Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes | Q82097295 | ||
| Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown | Q35791582 | ||
| Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. | Q35798412 | ||
| Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). | Q35810089 | ||
| Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. | Q35885116 | ||
| Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases | Q35961215 | ||
| Inhibitors of ocular neovascularization: promises and potential problems. | Q36077697 | ||
| Neutrophil-derived cytokines: potential therapeutic targets in inflammation. | Q36230445 | ||
| Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions | Q36237571 | ||
| Hereditary angioedema | Q36282895 | ||
| VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. | Q36371399 | ||
| Intravitreal triamcinolone acetonide: a change in a paradigm | Q36500994 | ||
| Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy | Q36608675 | ||
| Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration | Q36619213 | ||
| The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications | Q36657215 | ||
| Clinical pharmacokinetics and use of infliximab | Q36892770 | ||
| Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells | Q37101882 | ||
| Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy | Q37318352 | ||
| Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy | Q37356613 | ||
| Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo | Q37360588 | ||
| Advanced glycation end products increase retinal vascular endothelial growth factor expression | Q37379211 | ||
| Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin | Q37384532 | ||
| Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations | Q39697208 | ||
| Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. | Q40454968 | ||
| VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. | Q40595312 | ||
| Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. | Q40707728 | ||
| Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation | Q40937602 | ||
| Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. | Q41295542 | ||
| Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration | Q41711674 | ||
| Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor | Q42503628 | ||
| Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy | Q42756254 | ||
| Angiopoietin concentrations in diabetic retinopathy | Q43007236 | ||
| Increased prevalence of microthromboses in retinal capillaries of diabetic individuals | Q43618953 | ||
| VEGF-initiated blood-retinal barrier breakdown in early diabetes. | Q43723423 | ||
| In vivo retinal gene expression in early diabetes. | Q43785508 | ||
| Extensive deposits of complement C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy | Q43940024 | ||
| Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders | Q43946490 | ||
| Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy | Q44230956 | ||
| Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes | Q44244855 | ||
| Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina | Q44390940 | ||
| VEGF164Is Proinflammatory in the Diabetic Retina | Q44417311 | ||
| Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease | Q44429660 | ||
| Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema | Q44586436 | ||
| P433 | issue | 2 | |
| P921 | main subject | pathogenesis | Q372016 |
| P304 | page(s) | 65-84 | |
| P577 | publication date | 2008-03-14 | |
| P1433 | published in | Seminars in Immunopathology | Q15724576 |
| P1476 | title | Immunological mechanisms in the pathogenesis of diabetic retinopathy | |
| P478 | volume | 30 |
| Q50861252 | 1,25-Dihydroxyvitamin D3 Deficiency is Involved in the Pathogenesis of Diabetic Retinopathy in the Uygur Population of China. |
| Q92670822 | A cross-sectional study of vitreous and serum high mobility group box-1 levels in proliferative diabetic retinopathy |
| Q55384382 | A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. |
| Q36560394 | A population-based study of the risk of diabetic retinopathy in patients with type 1 diabetes and celiac disease |
| Q34370043 | A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus |
| Q34838463 | A(₂A) adenosine receptor (A(₂A)AR) as a therapeutic target in diabetic retinopathy |
| Q46434225 | Activated microglia induce the production of reactive oxygen species and promote apoptosis of co-cultured retinal microvascular pericytes |
| Q36990241 | Adeno-Associated Virus Overexpression of Angiotensin-Converting Enzyme-2 Reverses Diabetic Retinopathy in Type 1 Diabetes in Mice. |
| Q37634192 | Adenosine Deaminase-2-Induced Hyperpermeability in Human Retinal Vascular Endothelial Cells Is Suppressed by MicroRNA-146b-3p |
| Q37841990 | An integrated approach to diabetic retinopathy research |
| Q24658545 | Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials |
| Q34331514 | Angiogenic potential of vitreous from Proliferative Diabetic Retinopathy and Eales' Disease patients |
| Q51742251 | Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema. |
| Q41285088 | Arginase as a mediator of diabetic retinopathy |
| Q34800913 | Arginase in retinopathy |
| Q93047673 | Autoimmune-Mediated Retinopathy in CXCR5-Deficient Mice as the Result of Age-Related Macular Degeneration Associated Proteins Accumulation |
| Q37472290 | Basigin can be a therapeutic target to restore the retinal vascular barrier function in the mouse model of diabetic retinopathy |
| Q39727356 | Beneficial effects of a novel RAGE inhibitor on early diabetic retinopathy and tactile allodynia. |
| Q38715502 | Blocking IL-17A Alleviates Diabetic Retinopathy in Rodents |
| Q28584295 | Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes |
| Q39331082 | Canonical Wnt signaling in diabetic retinopathy. |
| Q47654688 | Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema. |
| Q34452944 | Changes to tear cytokines of type 2 diabetic patients with or without retinopathy |
| Q35346991 | Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy |
| Q89425254 | Comparison of early dexamethasone retreatment versus standard dexamethasone regimen combined with PRN ranibizumab in diabetic macular edema |
| Q34081378 | Comparison of three strains of diabetic rats with respect to the rate at which retinopathy and tactile allodynia develop |
| Q99612540 | Complement Activation in the Vitreous of Patients With Proliferative Diabetic Retinopathy |
| Q34374022 | Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis |
| Q33517638 | Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases |
| Q53115047 | Correlation of vascular endothelial growth factor plasma levels and glycemic control in patients with diabetic retinopathy. |
| Q37801912 | Current approaches to the management of diabetic retinopathy and diabetic macular oedema |
| Q34762469 | Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1α-VEGF pathway inhibition |
| Q34735196 | Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR) |
| Q34553087 | Diabetic Retinopathy-Update on Prevention Techniques, Present Therapies, and New Leads |
| Q30415630 | Diabetic macular edema: New promising therapies |
| Q33713517 | Diabetic macular edema: new concepts in patho-physiology and treatment |
| Q34091784 | Diabetic macular edema: new trends in management |
| Q36018006 | Diabetic macular oedema: pathophysiology, management challenges and treatment resistance |
| Q43039163 | Diabetic maculopathy and retinopathy. Functional and sociomedical significance |
| Q41012046 | Diabetic retinopathy and inflammation: novel therapeutic targets. |
| Q34448837 | Diabetic retinopathy: targeting vasoregression |
| Q100455039 | Differential reperfusion patterns in retinal vascular plexuses following increase in intraocular pressure an OCT angiography study |
| Q40979686 | Effect of Topical Nepafenac on Central Foveal Thickness following Panretinal Photocoagulation in Diabetic Patients |
| Q33845105 | Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function |
| Q51006585 | Elevated Activating Transcription Factor 4 and Glucose-Regulated 78 Kda Protein Levels Correlate with Inflammatory Cytokines in the Aqueous Humor and Vitreous of Proliferative Diabetic Retinopathy. |
| Q37684896 | Emerging roles of hematopoietic cells in the pathobiology of diabetic complications |
| Q37501293 | Epoxygenated Fatty Acids Inhibit Retinal Vascular Inflammation. |
| Q34047929 | Evaluation of leukocyte-endothelial interactions in retinal diseases |
| Q92773331 | Evaluation of vascular endothelial growth factor levels in tears and serum among diabetic patients |
| Q33518322 | Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation |
| Q26824693 | Eyeing central neurons in vascular growth and reparative angiogenesis |
| Q36232690 | GPR109A as an anti-inflammatory receptor in retinal pigment epithelial cells and its relevance to diabetic retinopathy |
| Q64958740 | HMBG1 as a Driver of Inflammatory and Immune Processes in the Pathogenesis of Ocular Diseases. |
| Q37843935 | Higher titers of anti-Chlamydia pneumoniae IgG in diabetic retinopathy: a cross-sectional study |
| Q58091078 | Hyperreflective foci on optical coherence tomography associate with treatment outcome for anti-VEGF in patients with diabetic macular edema |
| Q37538552 | IL-17A exacerbates diabetic retinopathy by impairing Müller cell function via Act1 signaling |
| Q37161442 | Increased levels of IL-6, sIL-6R, and sgp130 in the aqueous humor and serum of patients with diabetic retinopathy |
| Q49597740 | Increased postnatal concentrations of pro-inflammatory cytokines are associated with reduced IGF-I levels and retinopathy of prematurity |
| Q53532757 | Indications of lymphatic endothelial differentiation and endothelial progenitor cell activation in the pathology of proliferative diabetic retinopathy. |
| Q37884176 | Inflammation in diabetic retinopathy |
| Q51628940 | Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. |
| Q37095335 | Inflammatory biomarkers and progression of diabetic retinopathy in African Americans with type 1 diabetes |
| Q33562586 | Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study |
| Q34487307 | Inhibition of NOX1/4 with GKT137831: a potential novel treatment to attenuate neuroglial cell inflammation in the retina |
| Q47951826 | Inhibition of TLR4 alleviates the inflammation and apoptosis of retinal ganglion cells in high glucose. |
| Q33375711 | Interleukin-10 promotes pathological angiogenesis by regulating macrophage response to hypoxia during development |
| Q51811242 | Intraocular Inflammation in Diabetic Populations. |
| Q60911605 | Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials |
| Q41902127 | Intravitreal injection of ranibizumab and CTGF shRNA improves retinal gene expression and microvessel ultrastructure in a rodent model of diabetes |
| Q50228683 | Involvement of HMGB1 mediated signalling pathway in diabetic retinopathy: evidence from type 2 diabetic rats and ARPE-19 cells under diabetic condition |
| Q48095108 | Ischemic Retinopathies: Oxidative Stress and Inflammation. |
| Q39111812 | Leukocyte adhesion molecules in diabetic retinopathy |
| Q55003873 | Levels of Inflammatory Cytokines IL-1β, IL-6, IL-8, IL-17A, and TNF-α in Aqueous Humour of Patients with Diabetic Retinopathy. |
| Q37165322 | Lymphoblastoid Cell Lines as a Tool to Study Inter-Individual Differences in the Response to Glucose |
| Q37678807 | Mediators of ocular angiogenesis |
| Q58733408 | Microglia enhanced the angiogenesis, migration and proliferation of co-cultured RMECs |
| Q38463463 | Molecular mechanisms of diabetic retinopathy: potential therapeutic targets |
| Q34851558 | MyD88-dependent pathways in leukocytes affect the retina in diabetes |
| Q43711907 | Müller glial cells inhibit proliferation of retinal endothelial cells via TGF-β2 and Smad signaling. |
| Q43171711 | Neuropilin-1 mediates myeloid cell chemoattraction and influences retinal neuroimmune crosstalk. |
| Q36567310 | Nonsteroidal anti-inflammatory drugs for retinal disease |
| Q34688209 | Novel drugs and their targets in the potential treatment of diabetic retinopathy |
| Q28066675 | Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon? |
| Q49380314 | Novel therapeutic targets in diabetic macular edema: Beyond VEGF. |
| Q36128700 | Omega-3 polyunsaturated fatty acids preserve retinal function in type 2 diabetic mice |
| Q57802393 | One month of hyperglycemia alters spectral responses of the zebrafish photopic electroretinogram |
| Q36077775 | Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study |
| Q37226580 | Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives |
| Q34528134 | Pathophysiology and treatment of diabetic retinopathy |
| Q49384584 | Pharmacologic management of diabetic retinopathy |
| Q37242145 | Photoreceptor Cells Influence Retinal Vascular Degeneration in Mouse Models of Retinal Degeneration and Diabetes |
| Q43036015 | Plasma kallikrein and diabetic macular edema |
| Q52609620 | Potential Interplay between Hyperosmolarity and Inflammation on Retinal Pigmented Epithelium in Pathogenesis of Diabetic Retinopathy. |
| Q34575640 | Preconditioning with endoplasmic reticulum stress mitigates retinal endothelial inflammation via activation of X-box binding protein 1. |
| Q36035794 | Prevalence and risk factors of diabetic retinopathy in Chongqing pre-diabetes patients |
| Q53913493 | Profile of intraocular tumour necrosis factor-α and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy. |
| Q35073329 | Requirement of NOX2 expression in both retina and bone marrow for diabetes-induced retinal vascular injury |
| Q24647760 | Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory |
| Q37763230 | Retinal pigment epithelium differentiation of stem cells: current status and challenges |
| Q36065113 | Retinylamine Benefits Early Diabetic Retinopathy in Mice |
| Q35975219 | Rheumatoid arthritis and the prevalence of diabetic retinopathy |
| Q35873681 | Risk of Retinal Neovascularization in Cases of Uveitis |
| Q33845139 | Role of IL-6 in angiotensin II-induced retinal vascular inflammation |
| Q37023062 | Role of glyceraldehyde 3-phosphate dehydrogenase in the development and progression of diabetic retinopathy |
| Q38256054 | Role of inflammasome activation in the pathophysiology of vascular diseases of the neurovascular unit. |
| Q41012127 | Role of inflammation in the pathogenesis of diabetic retinopathy |
| Q36468930 | Role of matrix metalloproteinase-2 and -9 in the development of diabetic retinopathy |
| Q90728471 | Role of oxidative stress, inflammation, hypoxia and angiogenesis in the development of diabetic retinopathy |
| Q91735201 | STAT3 activation in circulating myeloid-derived cells contributes to retinal microvascular dysfunction in diabetes |
| Q36093262 | Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study |
| Q85925770 | Single injection of triamcinolone versus three repeated injections of bevacizumab for treatment of diabetic macular edema |
| Q36843303 | Sphingolipid profile alters in retinal dystrophic P23H-1 rats and systemic FTY720 can delay retinal degeneration |
| Q37071368 | Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy |
| Q37139437 | Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany) |
| Q28817495 | Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown |
| Q35005977 | TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis |
| Q38870510 | Targeting of 12/15-Lipoxygenase in retinal endothelial cells, but not in monocytes/macrophages, attenuates high glucose-induced retinal leukostasis |
| Q42340241 | Th17 cell frequency and IL-17A concentrations in peripheral blood mononuclear cells and vitreous fluid from patients with diabetic retinopathy |
| Q26748944 | The Adenosinergic System in Diabetic Retinopathy |
| Q35836955 | The Neuropilin-1 Inhibitor, ATWLPPR Peptide, Prevents Experimental Diabetes-Induced Retinal Injury by Preserving Vascular Integrity and Decreasing Oxidative Stress |
| Q33775122 | The alternative complement pathway regulates pathological angiogenesis in the retina |
| Q55395409 | The effects of bevacizumab treatment in a rat model of retinal ischemia and perfusion injury. |
| Q38077553 | The immunological basis of degenerative diseases of the eye. |
| Q34149599 | The pathogenesis of early retinal changes of diabetic retinopathy |
| Q38242801 | The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases. |
| Q37636897 | The safety, pharmacokinetics, and efficacy of intraocular celecoxib |
| Q35180049 | The unconventional role of acid sphingomyelinase in regulation of retinal microangiopathy in diabetic human and animal models |
| Q27021701 | Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy |
| Q38873909 | Therapeutic targeting of diabetic retinal neuropathy as a strategy in preventing diabetic retinopathy |
| Q37464743 | Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials |
| Q92452380 | Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN® (0.19 mg fluocinolone acetonide implant) |
| Q38162433 | Topical nonsteroidal anti-inflammatory drugs for macular edema. |
| Q30010106 | Transcriptome analysis using next generation sequencing reveals molecular signatures of diabetic retinopathy and efficacy of candidate drugs |
| Q93153704 | Transducin1, Phototransduction and the Development of Early Diabetic Retinopathy |
| Q58841511 | Treatment of macular edema in diabetic retinopathy: comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections |
| Q92860697 | Ursodeoxycholic Acid Attenuates the Retinal Vascular Abnormalities in Anti-PDGFR-β Antibody-Induced Pericyte Depletion Mouse Models |
| Q85244433 | VEGF and Refractive Error |
| Q27320203 | Vascular cellular adhesion molecule-1 (VCAM-1) expression in mice retinal vessels is affected by both hyperglycemia and hyperlipidemia |
| Q38693342 | Visfatin induces the apoptosis of endothelial progenitor cells via the induction of pro-inflammatory mediators through the NF-κB pathway |
| Q88013470 | Vitreous IL-8 and VEGF levels in diabetic macular edema with or without subretinal fluid |
| Q27028225 | Vitreous mediators in retinal hypoxic diseases |
| Q36049918 | Zingiber officinale attenuates retinal microvascular changes in diabetic rats via anti-inflammatory and antiangiogenic mechanisms |
| Q36197680 | cGMP-Phosphodiesterase Inhibition Prevents Hypoxia-Induced Cell Death Activation in Porcine Retinal Explants |
| Q36060465 | miR-126 Regulation of Angiogenesis in Age-Related Macular Degeneration in CNV Mouse Model |
Search more.